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Aim: We assessed the success rates of reaching glycated haemoglobin (HbA1c) goals in different treatment groups.
Materials and methods: This was a single-centre, retrospective study including 2995 patients. The proportion of patients reaching their
HbA1c goals, according to the International Diabetes Federation (IDF), American Association of Clinical Endocrinologists (AACE),
and American Diabetes Association (ADA), were determined.
Results: There were 4 different treatment groups: 1) diet group (n = 140), 2) oral antidiabetic drug (OAD) group (n = 1238), 3) insulin
group (n = 765), and 4) insulin + OAD group (n = 812). According to the IDF and AACE criteria, the proportion of patients reaching
HbA1c levels of ≤6.5% was 92% in group 1, and 1 year later it was 100%. In the OAD group the proportions were 61% and 69%,
respectively. In the insulin group, the rate was 15% and 1 year later 33% of patients had reached their goals. In the insulin + OAD group,
the rates were 10% and 21%, respectively (P < 0.05 for all). According to the ADA criteria, the rate of patients reaching HbA1c levels of
≤7% was 40% in the total group and, at the end of 1 year, 59%. In the diet group, the rates were 95% and 100%, respectively. In the OAD
group, the rates were 75% and 83%, respectively. In the insulin group, the rates were 23% and 52%, respectively. In the insulin + OAD
group, the rates were 16% and 32%, respectively.
Conclusion: A large number of patients seemed to reach their HbA1c goals. The success rate was especially higher in the OAD group
than in the insulin group.
Key words: HbA1c goals, oral antidiabetic drugs, insulin

1. Introduction
The amount of glycated haemoglobin (HbA1c) correlates
well with fasting and postprandial blood glucose levels
(1,2). In the Cost of Diabetes in Europe – Type 2 (CODE2) study, only 31% of individuals achieved good glycaemic
control (HbA1c = 6.5%) according to current European
guidelines (3). In the US National Health and Nutrition
Examination Survey (NHANES) of 1999–2000, only 37.0%
of participants achieved the target goal of HbA1c levels
less than 7.0%, and 37.2% of participants were above the
recommended “take action” HbA1c level of greater than
8.0% (4).
Despite evidence that good glycaemic control has
significant health and economic benefits, most patients
with diabetes do not achieve the recommended treatment
goals. According to studies conducted in the United
State, Europe, and Asia-Pacific, most patients have poor
glycaemic control (HbA1c > 8%); less than one-third,
and substantially less in some countries, achieve the
* Correspondence: seucak@yahoo.com

recommended target levels for HbA1c (3,5,6). For example,
in the DiabCare Asia Study (6), the mean HbA1c level was
8.6%, with only 21%, 13%, or 7% of patients achieving
recommended HbA1c goals according to the criteria of the
American Diabetes Association (ADA; <7%), the European
Diabetes Policy Group (≤6.5%), or the Asia Pacific Type
2 Diabetes Policy Group 1999 (APDPG; <6.2%; note that
the APDPG 2002 guidelines recommend a goal of ≤6.5%).
These data are supported by numerous other studies. For
instance, in the UK Asian Diabetes Study, a communitybased study conducted in Birmingham and Coventry in
the United Kingdom, 66% of patients had HbA1c levels
of >7% (7).
A very recent nationwide observational study from
Sweden reported that the proportion of patients reaching
HbA1c levels of ≤7% varied between 70.1% (metformin)
and 25.0% (premixed insulin + sulphonylureas) in patients
with pharmacological treatment, and that 84.8% of the
patients with nonpharmacological treatment reached their
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targets. Compared to patients on metformin, patients on
other pharmacological treatments had a lower likelihood
(with reported hazard ratios ranging from 0.58; 95%
confidence interval of 0.54–0.63 to 0.97; 0.94–0.99) of
having HbA1c levels of ≤7%, adjusted for covariates.
Patients on insulin-based treatments had the lowest
likelihood, while nonpharmacological treatment was
associated with an increased likelihood, of having HbA1c
levels of ≤7% (8).
There are no available data on patients’ diabetes
regulation rates in the Turkish population. The aim of this
study was to assess the success rates of reaching HbA1c
goals in different treatment groups in a Turkish population.
2. Materials and methods
2.1. Study design
This was a single-centre, retrospective study. All patients
with documented files who were screened during the
period of January 2005 to January 2006 were chosen in
succession and enrolled for the study. Patients were divided
into 4 different groups according to the treatment they were
started on, or were using, at the beginning of the study:
1) diet group, 2) oral antidiabetic drug (OAD) group, 3)
insulin group, and 4) insulin + OAD group. Patients who
had to change treatments because of inadequate glucose
control during the 1-year follow-up period were excluded
from the study. Patients who only needed dose adjustments
or additional agents and remained in the same treatment
group were not excluded. Having complications was not
an exclusion criterion.
2.2. Subjects
A total number of 3354 patients were admitted to our
diabetes outpatient clinic as a primary care unit in the
year 2005. All data were obtained from the patients’
files, which were archived in our outpatient clinic. Age,
sex, body mass index (BMI), duration of disease, type
of diabetes, number of visits in 1 year, HbA1c levels (for
3-month intervals in 1 year), and type of treatment were
evaluated. BMI was calculated by dividing weight in
kilograms by height in square metres. HbA1c levels were
measured by the high performance liquid chromatography
method. All parameters were also evaluated at a follow-up
at the end of 1 year. HbA1c levels were compared at the
beginning and the end of the study. The rate of patients
reaching the HbA1c goals according to the criteria of
the International Diabetes Federation (IDF), American
Association of Clinical Endocrinologists (AACE), and
ADA were determined. All parameters were compared
between different treatment groups. HbA1c levels were
also compared between patients with diabetes duration of
≥5 years or <5 years and ≥10 years or <10 years.
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2.3. Statistical analysis
Statistical analyses were performed with SPSS. Results are
expressed as the mean ± standard deviation of the mean
(SD). The Student t-test, repeated measurement variant
analyses, and Tukey and Wilcoxon methods were used
to compare parameters. A P value of less than 0.05 was
considered significant.
3. Results
A total of 3354 files were screened and 354 patients were
excluded because of a change in treatment groups during
the 1-year follow-up. Due to missing data in their files, 5
patients were dropped from the study. Thus, 2995 diabetic
patients were recruited for the study; 3.1% of the patients
had type 1 diabetes mellitus and 96.9% had type 2 diabetes
mellitus. There were 58.2% females and 41.8% males.
There were 4 different treatment groups: 1) diet group (n
= 140), 2) OAD group (n = 1238), 3) insulin group (n = 765),
and 4) insulin + OAD group (n = 812). At the beginning,
the mean HbA1c levels of the 4 groups were 5.65 ± 1.09%,
6.96 ± 1.71%, 9.28 ± 2.57%, and 9.30 ± 2.15%, respectively.
No significant difference was observed between groups 3
and 4, while all other groups were significantly different.
At the end of the study, the mean HbA1c levels of the 4
groups were 5.20 ± 0.57%, 6.36 ± 0.99%, 7.39 ± 1.38%, and
7.70 ± 1.49%, respectively. No significant difference was
determined between groups 1 and 2 or between groups 3 and
4. Other group comparisons were statistically significant. The
percentage reductions of HbA1c of the 4 groups were 0.45 ±
0.52, 0.30 ± 0.72, 1.89 ± 1.19, and 1.60 ± 0.66, respectively,
after treatment. The biggest reduction was observed in
group 3. The percentage reduction of HbA1c was greater in
groups 3 and 4 compared to groups 1 and 2. However, no
significant difference was determined between groups 1 and
2 or between groups 3 and 4. According to IDF and AACE
criteria, the percentage of patients reaching HbA1c levels of
≤6.5% was 32% in the total group. At the end of 1 year, it was
45%. In the diet group, 92% of patients, and 1 year later, 100%
of patients, had reached the goals. In the OAD group, the rate
was 61%, and the next year it was 69%. In the insulin group,
15% of patients, and 1 year later, 33% of patients, reached
the target HbA1c levels. In the insulin + OAD group, the
rates were 10% and 21%, respectively. All these changes were
statistically significant (P < 0.05; Table 1).
According to the ADA criteria, patients reaching
HbA1c levels of ≤7% were 40% in the total group and, at
the end of 1 year, 59%. In the diet group, 95% of patients,
and 1 year later, 100% of patients, had reached the goals.
In the OAD group, the rate was 75%, and the next year it
was 83%. In the insulin group, 23% of patients, and 1 year
later, 52% of patients, had reached the target HbA1c levels.
In the insulin + OAD group, the rates were 16% and 32%,
respectively. All these changes were statistically significant
(P < 0.05; Table 2).
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Table 1. Proportion of patients reaching HbA1c of ≤6.5% according to IDF and AACE criteria.
Group (n)

Beginning proportion (%)

1 year later (%)

P

Diet group (140)

92

100

0.01

OAD group (1238)

61

69

0.01

Insulin group (765)

15

33

0.01

OAD + insulin group (812)

10

21

0.01

Total group

32

45

0.01

3.1. Age
Group 3 was younger compared to group 2 and group 4 (P
= 0.004 and P = 0.001, respectively; Table 3).
3.2. BMI
Group 3 had lower BMI values compared to groups 1, 2,
and 4 (P = 0.001 for all). Group 2 had the highest BMI
values (Table 3).
3.3. Diabetes duration
Group 3 had the longest diabetes duration, and it was
significantly different from those of groups 1 and 2 (P =
0.001 for both), but not statistically different from group 4.
Group 4 also had a longer diabetes duration compared to
groups 1 and 2 (P = 0.001 for both; Table 3).
When patients with a diabetes duration of ≥5 years or
<5 years were compared at the beginning and 1 year later,
HbA1c levels were found to be higher in the ≥5-year group
(P = 0.001 and P = 0.004 respectively).

The same results were found when patients with
diabetes duration of ≥10 years or <10 years were compared
(P = 0.001; Table 4).
3.4. Number of visits
Group 4 had a higher number of visits compared to group
2 (P = 0.024; Table 3). In the OAD group, the number of
visits were decreasing while HbA1c levels were increasing
(R = –0.2, P = 0.001). In the insulin group a similar
correlation was observed between the number of visits and
HbA1c levels (R = –0.2, P = 0.005).
4. Discussion
A large number of patients with diabetes mellitus seem to
reach their HbA1c goals in different treatment groups in
the Turkish population.

Table 2. Proportion of patients reaching HbA1c of ≤7% according to ADA criteria.
Group (n)

Beginning proportion (%)

1 year later (%)

P

Diet group (140)

95

100

0.01

OAD group (1238)

75

83

0.01

Insulin group (765)

23

52

0.01

OAD + insulin group (812)

16

32

0.01

Total group

40

59

0.01

Table 3. Comparison of different parameters in different treatment groups.
Group 1

Group 2

Group 3

Group 4

P

Age (years)

54.84 ± 12.62

55.48 ± 10.94

53.55 ± 15.56

56.34 ± 10.46

0.001

BMI initial (kg/m2)

29.64 ± 5.56

31.67 ± 5.57

27.20 ± 5.60

30.93 ± 5.27

0.001

Diabetes duration (years)

2.95 ± 3.99

4.16 ± 4.88

8.36 ± 7.73

8.22 ± 6.43

0.001

Number of visits/year

2.13 ± 1.20

2.21 ± 1.26

2.23 ± 1.46

2.38 ± 1.42

0.024
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The percentage of patients reaching the HbA1c target
levels according to the IDF and the AACE was 45%, and
it was 59% according to the ADA criteria, in the overall
group in our study. The results were much better compared
to findings of CODE-2 and NHANES 1999–2000, which
were 31% and 37%, respectively (3,4).
The American College of Endocrinology and the
AACE adopted a target HbA1c of <6.5% at their diabetes
treatment consensus conference in 2001. They created a
series of detailed “Roadmaps to Achieve Glycemic Control
in Type 2 Diabetes Mellitus” for health care providers;
these roadmaps recommend detailed individualised
treatment regimens and advancement of therapy every 3
months until the target HbA1c is achieved.
Based on these studies, the recommendations of
the ADA position statement of 2008 included lowering
HbA1c to an average of 7%, which has clearly been shown
to reduce microvascular and neuropathic complications of
diabetes and, possibly, macrovascular disease. Therefore,
the HbA1c goal for nonpregnant adults in general is <7%.
Epidemiologic studies have suggested a small incremental
benefit to lowering HbA1c from 7% into the normal
range. Therefore, the HbA1c goal for selected individual
patients is as close to normal (<6%) as possible, without
significant hypoglycaemia. Less stringent HbA1c goals
may be appropriate for patients with a history of severe
hypoglycaemia, patients with limited life expectancies,
children, individuals with comorbid conditions, and
those with longstanding diabetes and minimal or stable
microvascular complications (1).
In 2006, the ADA and European Association for the
Study of Diabetes first published a consensus statement, in
which they provided an algorithm for the management of
hyperglycaemia in type 2 diabetes mellitus (9). A revision
of the consensus statement was published in early 2009
(10). The glycaemic management goal recommended in
the algorithm is the attainment and maintenance of an
HbA1c level of <7.0%. Some organisations, such as the
AACE, have set more aggressive goals (11).
Recently concluded studies reveal that targeting HbA1c
levels below 7.0% may not be a viable option anymore.
Furthermore, achieving tight blood glucose control is
easier said than done due to the risks of hypoglycaemia
and treatment-induced weight gain (11,12).
Another study, “The Action to Control Cardiovascular
Risk in Diabetes (ACCORD)”, conducted in middleaged or older type 2 diabetics and patients with high
cardiovascular risk, compared the benefits of intensive
treatment (an HbA1c target of <6.0%) with standard
treatment (HbA1c target of 7.0%–7.9%). After an average
treatment period of 4 years, the intensive therapy arm of
the study was abandoned due to increased mortality in
comparison to the standard treatment group. The reasons
for the increased mortality are as of yet undetermined;
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however, it is clearly seen that intensive treatment was
not beneficial to the high-risk patients. However, in other
studies, such as Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled
Evaluation (ADVANCE), the findings were not in
agreement with those of ACCORD (13,14).
The incidence of clinical complications of diabetes is
strongly associated with glycaemia. Each 1% reduction in
updated mean HbA1c is associated with a risk reduction of
21% for diabetes-related complications, 21% for diabetesrelated deaths, 14% for myocardial infarction, and 37% for
microvascular complications (15–18).
In our study, nearly half of all patients reached their
HbA1c targets. In the OAD group, targets of ≤6.5% and
≤7% were reached at rates of 69% and 83%, respectively.
In the insulin group, these rates were 33% and 52%. All
groups showed significant positive changes compared to
initial HbA1c levels after 1 year. The percentage reduction
of HbA1c was greater in the insulin and insulin + OAD
groups compared to the diet and OAD groups. This could
be explained by the fact that groups 3 and 4 had higher
levels of HbA1c at the beginning. Although a higher
reduction was observed in HbA1c percentages in groups
3 and 4, larger numbers of patients in the OAD and diet
groups reached their target levels.
Group 2 had the highest initial BMI levels compared to
the other groups. The lowest BMI was observed in group 3.
These results suggest the presence of insulin resistance in
group 2 and decreased beta cell function in group 3.
Groups 3 and 4 had longer diabetes durations
compared to the other 2 groups. They were older diabetics
and received insulin therapy. Both OAD and insulin users
showed a negative correlation between the number of
visits and HbA1c levels, suggesting that more visits are
necessary for better glycaemic control.
When patients with diabetes duration of ≥5 years or <5
years or with diabetes duration of ≥10 years or <10 years
were compared, it was found that patients with a longer
diabetes duration had higher HbA1c levels.
From a clinician’s point of view, all of these studies and
guidelines fail to point out a clear target in HbA1c, mainly
due to the varying results of 3 recently concluded major
studies (ADVANCE, ACCORD, and the Veterans Affairs
Diabetes Trial). On one hand, a curvilinear correlation
in the reduction of HbA1c and the prevention of diabetic
complications suggests a lower target of HbA1c for patients,
but on the other hand, risks of severe hypoglycaemic
episodes, weight gain, and increased risk of cardiovascular
events raise some points of concern.
Regardless of clinicians’ perspectives on whether to
target a level of <7% or <6.5%, in our study we showed
that more than 60% of our patients using OADs reached
their HbA1c target. This may be explained due to a shorter
duration of disease in patients using OADs and better
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compliance to their therapy regimens. On the contrary,
just 21%–33% of patients using insulin reached the target
of <6.5%. However, these results were better than the
quoted results in major studies. Although the percentage
reductions in HbA1c were greater in insulin-treated
groups, more patients in the OAD-treated group reached
the targets, which might be due to lower starting levels of
HbA1c in this group. The facts that a competent nurse was
present to educate our patients and that the patients made
more frequent visits to our clinic possibly contributed to
our better results. Highlighted in our study is the fact that
there is a negative correlation between the frequency of
visits and HbA1c levels.

We can frankly admit to the fact that neither the
frequency of hypoglycaemic episodes nor the weight
gain of patients was evaluated in our study, which may
be considered a weakness. However, our primary focus
was the evaluation of our patients’ success in reaching the
HbA1c targets.
In conclusion, the success rates of Turkish diabetic
patients in reaching their target HbA1c levels are
considerably better than in other studies. The rate was
especially greater in the OAD group than in the insulin
group. This might be due to the fact that patients under
OAD treatment have a shorter duration of diabetes and
better compliance to their therapy regimen.
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